Similar articles for PMID: 23201762

Year	Number of Results
1980	1
1995	1
1996	1
1998	3
2000	2
2001	3
2002	1
2003	3
2004	1
2005	2
2006	5
2007	5
2008	4
2009	3
2010	5
2011	4
2012	8
2013	4
2014	7
2015	8
2016	8
2017	8
2018	7
2019	8
2020	9
2021	17
2022	20
2023	4
2024	0

1

Dysregulation of glutathione homeostasis in neurodegenerative diseases.

Johnson WM, Wilson-Delfosse AL, Mieyal JJ. Johnson WM, et al. Nutrients. 2012 Oct 9;4(10):1399-440. doi: 10.3390/nu4101399. Nutrients. 2012. PMID: 23201762 Free PMC article. Review.

2

The transition metals copper and iron in neurodegenerative diseases.

Rivera-Mancía S, Pérez-Neri I, Ríos C, Tristán-López L, Rivera-Espinosa L, Montes S. Rivera-Mancía S, et al. Chem Biol Interact. 2010 Jul 30;186(2):184-99. doi: 10.1016/j.cbi.2010.04.010. Epub 2010 May 14. Chem Biol Interact. 2010. PMID: 20399203 Review.

3

Mitochondrial diseases of the brain.

Chaturvedi RK, Flint Beal M. Chaturvedi RK, et al. Free Radic Biol Med. 2013 Oct;63:1-29. doi: 10.1016/j.freeradbiomed.2013.03.018. Epub 2013 Apr 6. Free Radic Biol Med. 2013. PMID: 23567191 Review.

4

Biological metals and metal-targeting compounds in major neurodegenerative diseases.

Barnham KJ, Bush AI. Barnham KJ, et al. Chem Soc Rev. 2014 Oct 7;43(19):6727-49. doi: 10.1039/c4cs00138a. Epub 2014 Aug 7. Chem Soc Rev. 2014. PMID: 25099276 Review.

5

Neurodegenerative diseases and therapeutic strategies using iron chelators.

Ward RJ, Dexter DT, Crichton RR. Ward RJ, et al. J Trace Elem Med Biol. 2015;31:267-73. doi: 10.1016/j.jtemb.2014.12.012. Epub 2015 Jan 22. J Trace Elem Med Biol. 2015. PMID: 25716300 Free article. Review.

6

Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.

Calabrese V, Lodi R, Tonon C, D'Agata V, Sapienza M, Scapagnini G, Mangiameli A, Pennisi G, Stella AM, Butterfield DA. Calabrese V, et al. J Neurol Sci. 2005 Jun 15;233(1-2):145-62. doi: 10.1016/j.jns.2005.03.012. J Neurol Sci. 2005. PMID: 15896810 Review.

7

The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications.

Perry G, Sayre LM, Atwood CS, Castellani RJ, Cash AD, Rottkamp CA, Smith MA. Perry G, et al. CNS Drugs. 2002;16(5):339-52. doi: 10.2165/00023210-200216050-00006. CNS Drugs. 2002. PMID: 11994023 Review.

8

Resveratrol: A Focus on Several Neurodegenerative Diseases.

Tellone E, Galtieri A, Russo A, Giardina B, Ficarra S. Tellone E, et al. Oxid Med Cell Longev. 2015;2015:392169. doi: 10.1155/2015/392169. Epub 2015 Jun 9. Oxid Med Cell Longev. 2015. PMID: 26180587 Free PMC article. Review.

9

Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system.

Aymerich MS, Aso E, Abellanas MA, Tolon RM, Ramos JA, Ferrer I, Romero J, Fernández-Ruiz J. Aymerich MS, et al. Biochem Pharmacol. 2018 Nov;157:67-84. doi: 10.1016/j.bcp.2018.08.016. Epub 2018 Aug 17. Biochem Pharmacol. 2018. PMID: 30121249 Free article. Review.

10

Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.

Ciechanover A, Kwon YT. Ciechanover A, et al. Exp Mol Med. 2015 Mar 13;47(3):e147. doi: 10.1038/emm.2014.117. Exp Mol Med. 2015. PMID: 25766616 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

140 results

Results by year